Taylor & Francis Group
Browse
supplementary figure 1.pdf (1022.45 kB)

Supplementary figure 1.pdf: A Phase I trial of talazoparib in patients with advanced hematologic malignancies

Download (1022.45 kB)
figure
posted on 2021-10-23, 12:03 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti
Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib.

Funding

This study was sponsored by Biomarin/Medivation, which was acquired by Pfizer Inc. in September 2016 (grant number not applicable).

History

Usage metrics

    International Journal of Hematologic Oncology

    Categories

    Keywords

    Poly(ADP-ribose) polymerase inhibitiontalazoparibhematologic malignancyDNA damage responseBRCA1/2 mutationsHematology

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC